Clinical trials
Acute Leukemia clinical trials
Below are recruiting acute leukemia clinical trials, each written for real people, not researchers. We’re tracking 940 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07761533RecruitingPhase 1/Phase 2
PBSS1113 plus azacitidine for blood cancers
This study tests a new drug (PBSS1113) combined with azacitidine for people with certain blood cancers (AML or high-risk MDS). The goal is to see if the combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT06323044Recruiting
Support program for parents giving daily leukemia medicine
This study tests a support program that helps parents give their child's daily leukemia medicine (6-MP) on schedule and overcome any barriers. It aims to make it easier for families to stick with treatment.
Buffalo, New YorkAges Any age - NCT05188170RecruitingPhase 1
Niclosamide for children and young adults with difficult leukemia
This Phase 1 study tests niclosamide, a medicine being studied as a new treatment, for pediatric and young adult AML that has come back or did not respond. It mainly focuses on whether the drug can be given safely and what dose might work best.
Palo Alto, CaliforniaAges 2–25 - NCT05444348Recruiting
Communication and care-planning support for blood cancer patients
This study tests an approach to help people with certain blood cancers and their main caregiver plan ahead and communicate more clearly about end-of-life care. It may help patients feel more supported and better prepared for difficult decisions.
AalborgAges 18 years+ - NCT07756034Recruiting
Cancer data registry for patients in the U.S.
This study collects information from people with cancer to help researchers learn more about the disease. You may join a general cancer registry or, if your child has a specific type of leukemia, a special part of the study.
Chicago, IllinoisAges Any age - NCT07751991RecruitingPhase 1
Study of a new drug for relapsed AML with specific genetic changes
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Grand Rapids, MichiganAges 18 years+ - NCT06265545Recruiting
Study for relapsed or hard-to-treat AML
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
TianjinAges Any age - NCT06756022Recruiting
Dolasetron to prevent nausea from chemo in kids with leukemia
This trial tests if a medicine called dolasetron can prevent chemotherapy-related nausea and vomiting in children with acute lymphoblastic leukemia (ALL). It may help kids feel better during their first round of treatment.
Hefei, AnhuiAges 2–17 - NCT06061094RecruitingPhase 2
Ph+ ALL chemo with targeted pills and transplant
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
AachenAges 18–65 - NCT05881265RecruitingPhase 2
Chidamide plus venetoclax for hard-to-treat APL
This trial studies chidamide and venetoclax in people with a specific type of acute promyelocytic leukemia (APL) that has not responded to standard treatment with all-trans retinoic acid (RA) plus arsenic. It may help by testing a new combination for cases in “non-remission” status.
Huai'an, JiangsuAges 16–70 - NCT05024552RecruitingPhase 1
Vyxeos plus gilteritinib for certain relapsed AML
This Phase 1 trial studies whether combining Vyxeos (a chemotherapy) with gilteritinib (a targeted drug) can treat AML that has come back or hasn’t responded well, specifically AML with certain FLT3 mutations. If it works, it could improve chances of controlling the leukemia.
Tampa, FloridaAges 18 years+ - NCT03031249Enrolling by invitationPhase 1/Phase 2
Testing ATO plus ATRA for NPM1-mutated AML after remission
This trial studies whether a combination medicine (ATO plus ATRA) is safe and works better in people with a specific type of AML (acute myeloid leukemia) caused by an NPM1 mutation. You would join only after your leukemia has reached remission, meaning the active leukemia has cleared after initial treatment.
Tianjin, Tianjin MunicipalityAges 14–55 - NCT07162116RecruitingPhase 1
Effect of XY0206 on heart rhythm in healthy Chinese volunteers
This trial tests whether a new drug called XY0206 affects the heart's electrical activity (QTc interval). Healthy participants take either XY0206, a placebo, or a control drug to compare effects. It helps ensure the drug is safe for the heart before testing in patients.
Zibo, ShandongAges 18–45 - NCT06346912RecruitingEarly Phase 1
CAR-T cell therapy for relapsed B-cell blood cancers
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT06262438RecruitingPhase 2
Quizartinib plus chemo for children with FLT3-ITD AML
This study adds a targeted drug called quizartinib to standard chemotherapy for children with a certain type of acute myeloid leukemia (AML) that has a FLT3-ITD gene change. The goal is to see if this combination is safe and effective for treating newly diagnosed patients.
Utrecht, UtrechtAges 1 month–18 years - NCT06744504RecruitingPhase 3
Comparing two chemo doses for a type of AML with a specific genetic change
This trial tests whether a higher dose of cytarabine (a chemotherapy drug) is better than the standard dose for treating acute myeloid leukemia (AML) that has a specific gene change called RUNX1-RUNX1T1. It aims to find the most effective induction therapy for this subtype.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT07163793RecruitingPhase 2
Shorter venetoclax after AML remission
This trial is testing if a shorter course of venetoclax can still work well after you've already achieved remission with standard venetoclax-based treatment for AML. The goal is to reduce side effects while keeping the cancer under control.
New Hyde Park, New YorkAges 18 years+ - NCT06083129RecruitingPhase 3
Preventing GVHD after stem cell transplant in older adults
This trial tests two different medicines (ATG-thymoglobulin and ATLG-grafalon) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for older adults with certain blood cancers who have a matched unrelated donor.
AmiensAges 50–70 - NCT06366789RecruitingPhase 1
Testing a new drug for AML with FLT3 or spliceosome mutations
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Los Angeles, CaliforniaAges 18 years+ - NCT06447090RecruitingPhase 2
VMAC plus donor cells for AML relapse after transplant
This study tests a combination treatment called VMAC (a chemotherapy) plus DLI (donor immune cells) for people whose AML has returned after a stem cell transplant. The goal is to see if this approach can help control the leukemia again.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07503730RecruitingPhase 3
Early use of realgar-indigo naturalis formula plus ATRA for APL patients
This trial tests whether giving a combination of two oral medicines—realgar-indigo naturalis formula (RIF) and all-trans retinoic acid (ATRA)—early in treatment can help people with acute promyelocytic leukemia (APL), a specific type of blood cancer. The goal is to see if this approach works better than current standard care.
Xi'an, ShaanxiAges 18–80 - NCT07617285RecruitingPhase 1
CAR-T cell therapy for relapsed or refractory acute myeloid leukemia
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
BeijingAges 18–70 - NCT05736978RecruitingPhase 2
Tailored treatment for AML based on day-14 MRD test
This phase 2 study tests whether doctors can choose the best AML treatment plan using a special blood/marrow test done on day 14. It may help people who are not good candidates for intensive chemotherapy by adjusting therapy based on early response.
ShanghaiAges 18 years+ - NCT07246707RecruitingPhase 1
KSV01 injection for relapsed or refractory B-cell acute lymphoblastic leukemia
This trial tests an investigational drug called KSV01 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or hasn't responded to standard treatments. It aims to see if the drug can help control the cancer.
HangzhouAges 18–80
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute leukemia?
- Yes. Clin2 currently lists 940 recruiting acute leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.